Vaccination strategies for future influenza pandemics: A severity-based cost effectiveness analysis

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Kelso, Joel K ^a   Halder, Nilimesh ^a   Milne, George J ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antiviral medication; Cost effectiveness; Pandemic influenza; Social distancing; Vaccination

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; NONHUMAN; OUTCOME ASSESSMENT; PANDEMIC INFLUENZA; SENSITIVITY ANALYSIS; SYNDROME DELINEATION; TREATMENT PLANNING; VACCINATION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS; TIME FACTORS; YOUNG ADULT;

EID: 84873500884     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-81     Document Type: Article

References (55)

1. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012, 12(9):687-695. 10.1016/S1473-3099(12)70121-4, 22738893.
2. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998, 178(1):53-60. 10.1086/515616, 9652423.
3. Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev 1996, 18(1):64-76. 10.1093/oxfordjournals.epirev.a017917, 8877331.
4. Frost W. Statistics of influenza morbidity with special reference to certain factors in case incidence and case fatality. Public Heath Report 1920, 35:584-597.
5. Phillip C. Nature outlook: influenza. Nature 2011, 480(7376 Suppl):S1-S15.
6. Li F, Choi B, Sly T, Pak A. Finding the real case-fatality rate of H5N1 avian influenza. J Epidemiol Community Health 2008, 62(6):555-559. 10.1136/jech.2007.064030, 18477756.
7. Herfst S, Schrauwen EJA, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell EM, Bestebroer TM, Burke DF, Smith DJ. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012, 336(6088):1534-1541. 10.1126/science.1213362, 22723413.
8. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012, 420:420-428.
9. Russell CA, Fonville JM, Brown AEX, Burke DF, Smith DL, James SL, Herfst S, van Boheemen S, Linster M, Schrauwen EJ. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 2012, 336(6088):1541-1547. 10.1126/science.1222526, 3426314, 22723414.
10. Australian Health Management Plan for Pandemic Influenza [http://www.flupandemic.gov.au/internet/panflu/publishing.nsf/Content/ahmppi-1].
11. Pandemic Influenza Plan [http://www.hhs.gov/pandemicflu/plan/].
12. Pandemic flu: A national framework for responding to an influenza pandemic [http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_080734].
13. Perlroth DJ, Glass RJ, Davey VJ, Cannon D, Garber AM, Owens DK. Health outcomes and costs of community mitigation strategies for an influenza pandemic in the United States. Clin Infect Dis 2009, 50:165-174.
14. Sander B, Nizam A, Garrison LP, Postma MJ, Halloran EM, Longini IM. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health 2009, 12(2):226-233. 10.1111/j.1524-4733.2008.00437.x, 18671770.
15. Smith RD, Keogh-Brown MR, Barnett T, Tait J. The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment. Br Med J 2009, 339:b4571.
16. Halder N, Kelso J, Milne G. Cost-effective strategies for mitigating a future influenza pandemic with H1N1 2009 characteristics. PLoS One 2011, 6(7):e22087. 10.1371/journal.pone.0022087, 3132288, 21760957.
17. US Centers for Disease Control Interim pre-pandemic planning guidance: community strategy for pandemic influenza mitigation in the United States 2007, URL [http://www.flu.gov/planning-preparedness/community/community_mitigation.pdf], US Centers for Disease Control.
18. Fraser C, Christl DA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, Griffin J, Baggaley RF, Jenkins HE, Lyons EJ, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009, 324:1557-1561. 10.1126/science.1176062, 19433588.
19. Kelly H, Mercer G, Fielding J, Dowse G, Glass K, Carcione D, Grant KA, Effler PV, Lester RA, Gravenor MB. Pandemic (H1N1) 2009 influenza community transmission was established in one Australian state when the virus was first identified in North America. PLoS One 2010, 5(6):e11341. 10.1371/journal.pone.0011341, 2893203, 20596536.
20. Nishiura H, Chowell G, Safan M, Castillo-Chavez C. Pros and cons of estimating the reproduction number from early epidemic growth rate of influenza A(H1N1) 2009. Theor Biol Med Model 2010, 7:1-9. 10.1186/1742-4682-7-1, 2821365, 20056004.
21. Vynnycky E, Edmunds W. Analyses of the 1957 (Asian) influenza pandemic in the United Kingdom and the impact of school closures. Epidemiol Infect 2008, 136(2):166-179. 2870798, 17445311.
22. Viboud C, Tam T, Fleming D, Handel A, Miller MA, Simonsen L. Transmissibility and mortality impact of epidemic and pandemic influenza, with emphasis on the unusually deadly 1951 epidemic. Vaccine 2006, 24(44):6701-6707. 10.1016/j.vaccine.2006.05.067, 16806596.
23. Longini I, Halloran M, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004, 159(7):623-633. 10.1093/aje/kwh092, 15033640.
24. Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S. Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis 2005, 11(9):1355-1362. 10.3201/eid1209.041344, 3371825, 16229762.
25. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature 2004, 432:904-906. 10.1038/nature03063, 15602562.
26. Mathews JD, McCaw CT, McBryde JMES, McCaw JM. A biological model for influenza transmission: pandemic planning implications of asymptomatic infection and immunity. PLoS One 2007, 11:1-6.
27. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(25):2405-2413. 10.1056/NEJMoa0907413, 19745216.
28. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster J-M, Leroux-Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic infl uenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589. 10.1016/S0140-6736(07)61297-5, 17707753.
29. Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008, 3(2):e1665. 10.1371/journal.pone.0001665, 2253495, 18301743.
30. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006, 368:991-997. 10.1016/S0140-6736(06)69294-5, 16980114.
31. Milne G, Kelso J, Kelly H. Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines. J R Soc Interface 2010, 7:573-586. 10.1098/rsif.2009.0312, 2842780, 19755499.
32. Mylius SD, Hagenaars TJ, Lugner AK, Wallinga J. Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine 2008, 26:3742-3749. 10.1016/j.vaccine.2008.04.043, 18524428.
33. Halder N, Kelso J, Milne G. Developing guidelines for school closure interventions to be used during a future influenza pandemic. BMC Infect Dis 2010, 10(1):221. 10.1186/1471-2334-10-221, 2915996, 20659348.
34. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 2006, 442:448-452. 10.1038/nature04795, 16642006.
35. Germann TC, Kadau K, Longini IM, Macken CA. Mitigation strategies for pandemic influenza in the United States. PNAS 2006, 103(15):5935-5941. 10.1073/pnas.0601266103, 1458676, 16585506.
36. Glass RJ, Glass LM, Beyeler WE, Min HJ. Targeted social distancing design for pandemic influenza. Emerg Infect Dis 2006, 12(11):1671-1681. 10.3201/eid1211.060255, 3372334, 17283616.
37. Davey VJ, Glass RJ, Min HJ, Beyeler WE, Glass LM. Effective, robust design of community mitigation for pandemic influenza: a systematic examination of proposed US guidance. PLoS One 2008, 3(7):e2606. 10.1371/journal.pone.0002606, 2432023, 18596963.
38. Wu JT, Riley S, Fraser C, Leung GM. Reducing the impact of the next influenza pandemic using household-based public health interventions. PLoS Med 2006, 3(9):1532-1540.
39. Milne GJ, Kelso JK, Kelly HA, Huband ST, McVernon J. A small community model for the transmission of infectious diseases: comparison of school closure as an intervention in individual-based models of an influenza pandemic. PLoS One 2008, 3(12):e4005. 10.1371/journal.pone.0004005, 2602849, 19104659.
40. Halder N, Kelso J, Milne G. Analysis of the effectiveness of interventions used during the 2009 H1N1 influenza pandemic. BMC Publ Health 2010, 10:168.
41. Cauchemez S, Carrat F, Viboud C, Valleron A, Boelle P. A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data. Stat Med 2004, 23(22):3469-3487. 10.1002/sim.1912, 15505892.
42. Cauchemez S, Valleron A-J, Boelle P-Y, Flahault A, Ferguson NM. Estimating the impact of school closure on influenza transmission from Sentinel data. Nature Letters 2008, 452:750-755.
43. Papoulis A. Probability, random variables and stochastic processes 1984, New York: McGraw-Hill, 2.
44. Wallinga J, Lipsitch M. How generation intervals shape the relationship between growth rates and reproductive numbers. Proceedings of the Royal Society B: Biological Sciences 2007, 274(1609):599-604. 10.1098/rspb.2006.3754, 1766383, 17476782.
45. ECDC ECDC Risk Assessment 2009 influenza A(H1N1) pandemic Version 7. ECDC Risk Assessemnt 2009, Stockholm: European Center for Disease Control, ECDC.
46. Presanis AM, De Angelis D, Hagy A, Reed C, Riley S, Cooper BS, Finella L, Biedrzyki P, Lipsitch M, The New York City Swine Flu Investiation Team The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis. PLoS Med 2009, 6(12):e1000207. 10.1371/journal.pmed.1000207, 2784967, 19997612, The New York City Swine Flu Investiation Team.
47. Rawlins MD, Culyer AJ. National institute for clinical excellence and its value judgments. BMJ 2004, 329(7459):224-227. 10.1136/bmj.329.7459.224, 487742, 15271836.
48. Longini IM, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DAT, Halloran ME. Containing pandemic influenza at the source. Science 2005, 309:1083-1088. 10.1126/science.1115717, 16079251.
49. Ciofi degli Atti ML, Merler S, Rizzo C, Ajelli M, Massari M, Manfredi P, Furlanello C, Tomba GS, Iannelli M. Mitigation measures for pandemic influenza in Italy: an individual based model considering different scenarios. PLoS One 2008, 3(3):1-11.
50. Andradottir S, Chiu W, Goldsman D, Lee ML, Tsui KL, Sander B, Fisman DN, Nizam A. Reactive strategies for containing developing outbreaks of pandemic influenza. BMC Publ Health 2011, 11(Suppl 1):S1.
51. Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, Dunham KM, Meltzer MI. Cost-effectiveness of 2009 pandemic influenza A (H1N1) vaccination in the United States. PLoS One 2011, 6(7):e22308. 10.1371/journal.pone.0022308, 3146485, 21829456.
52. Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and cost-effectiveness of vaccination against pandemic (H1N1) 2009. Ann Intern Med 2009, 151(12):829. 10.7326/0000605-200912150-00157, 3250217, 20008759.
53. de Blasio BF, Iversen BG, Tomba GS. Effect of vaccines and antivirals during the major 2009 a (H1N1) pandemic wave in norway - and the influence of vaccination timing. PLoS One 2012, 7(1):e30018. 10.1371/journal.pone.0030018, 3254636, 22253862.
54. Conway JM, Tuite AR, Fisman DN, Hupert N, Meza R, Davoudi B, English K, van den Driessche P, Brauer F, Ma J. Vaccination against 2009 pandemic H1N1 in a population dynamical model of Vancouver, Canada: timing is everything. BMC Publ Health 2011, 11(1):932.
55. Newall AT, Wood JG, Oudin N, MacIntyre CR. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies. Emerg Infect Dis 2010, 16(2):224-230. 10.3201/eid1602.090571, 2957998, 20113551.